Related Experiment Video
Updated: Jun 21, 2026
Intra-lymph Node Injection of Biodegradable Polymer Particles
Published on: January 2, 2014
Cationic and Biocompatible Polymer/Lipid Nanoparticles as Immunoadjuvants.
Yunys Pérez-Betancourt1, Péricles Marques Araujo1, Bianca de Carvalho Lins Fernandes Távora2,3
1Biocolloids Laboratory, Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, Avenida Professor Lineu Prestes, 748 Butantan, São Paulo 05508-000, Brazil.
Novel hybrid nanoparticles (NPs) combining poly(methyl methacrylate) (PMMA) and dioctadecyl dimethyl ammonium bromide (DODAB) show promise as effective immunoadjuvants. These cationic NPs successfully adsorbed ovalbumin (OVA) and induced robust cellular and humoral immune responses for vaccine development.
Area of Science:
- Biomaterials Science
- Immunology
- Nanotechnology
Background:
- Nanostructures are crucial for developing effective immunoadjuvants.
- Ideal immunoadjuvants must be cationic, non-cytotoxic, and capable of complexing with antigens like proteins or nucleic acids.
- Existing DODAB-based adjuvants face challenges with biocompatibility.
Purpose of the Study:
- To develop novel hybrid nanoparticles (NPs) for vaccine applications.
- To create cationic, biocompatible NPs by combining PMMA and DODAB.
- To evaluate the adjuvant properties and immune response elicited by these novel NPs.
Main Methods:
- Synthesized hybrid NPs using emulsion polymerization of methyl methacrylate (MMA) in the presence of DODAB.
- Adsorbed ovalbumin (OVA) as a model antigen onto the synthesized NPs.
- Assessed the adjuvant properties and induced immune responses (cellular and humoral).
Main Results:
- Optimal hybrid NPs were successfully fabricated from PMMA and DODAB.
- The NPs effectively adsorbed the model antigen OVA.
- A significant dual immune response (cellular and humoral) was observed, overcoming DODAB's limitations.
Conclusions:
- The novel PMMA-DODAB hybrid NPs demonstrate potent immunoadjuvant capabilities.
- These NPs offer improved biocompatibility compared to previous DODAB-based adjuvants.
- The findings suggest potential applications for these NPs in diverse vaccine formulations.
